Breast fibroadenoma is a benign lesion and arises from the proliferation of the breast tissue. Fibroadenomas occur at any age, but more so in women below the age of 30 years. There are different types, namely simple, giant juvenile, and multicentric fibroadenomas. Women who have a history of fibroadenomas have an increased risk of developing breast cancer [1]. Conversely, fibroadenomas in themselves have little chance (up to 0.125%) of undergoing malignant change [2]. Younger women, those with a history of a breast mass, and women of African descent are at a greater risk for developing fibroadenomas. Protective factors include the use of combined oral contraceptive pills and greater parity.

The majority of women have simple fibroadenomas and present with a single painless, smooth, mobile breast mass with a rubbery consistency, most often located in the upper outer quadrant. The average size of lesions is about 2-3 centimeters.

10%–25% of affected women have multicentric fibroadenomas [3]. These can occur in any quadrant of the breast. Giant juvenile fibroadenomas make up between 0.5% and 2% of all fibroadenomas [4] [5]. They are typically seen in adolescent girls, and are usually unilateral and grow rapidly, with a weight of more than 500 grams or diameter over 5 cm. They cause distortion and displacement of surrounding breast tissue, and may even cause skin changes and a distension of superficial veins [6].

The size of fibroadenomas may fluctuate, with a general tendency to decrease over time. They may enlarge or shrink in response to hormonal changes during the menstrual cycle and are particularly sensitive to estrogen [5]. Up to 40% of all fibroadenomas in adolescents resolve spontaneously.

Triple assessment may be used to investigate breast fibroadenoma. This includes clinical examination, imaging, and biopsy. It is important to take a full gynecological history, as well as the history of the presenting mass. A family history should also be taken, with emphasis on breast masses and malignancies. Physical examination of the breasts and axillary lymph nodes is mandatory in determining the characteristics of the mass.

Medical imaging modalities are a major part of the assessment of breast masses. Ultrasonography is widely used, especially in young women, and is advantageous when examining this population as they have dense breast tissue [7]. Mammography may be done and is especially advised for women over the age of 35 years. Magnetic resonance imaging (MRI) scanning is also useful and is a more sensitive test than mammography [8]. Follow up visits for repeated imaging is indicated for fibroadenomas [9].

Biopsy does not always need to be performed, especially when imaging suggests fibroadenoma, and in women in their 20s or younger. In postmenopausal women, however, breast lesions should be biopsied because of the greater chance of malignancy. Giant juvenile fibroadenomas should also be biopsied, as they resemble malignancies.

Treatment for fibroadenoma depends on the size of the tumor, symptoms, and patient preference. Many fibroadenomas do not require treatment and can be monitored with regular follow-up exams and imaging. If the fibroadenoma is large, painful, or causing anxiety, surgical removal may be considered. Minimally invasive procedures, such as cryoablation (freezing the tumor), are also options for some patients.

The prognosis for fibroadenoma is excellent, as these tumors are benign and do not increase the risk of breast cancer. Most fibroadenomas remain stable or shrink over time, especially after menopause. Regular monitoring is usually sufficient to ensure that no changes occur that might suggest a different diagnosis.

The exact cause of fibroadenoma is not well understood, but it is believed to be related to hormonal factors, particularly estrogen. This is supported by the fact that fibroadenomas are most common in women of reproductive age and may change in size with hormonal fluctuations, such as during pregnancy or hormone therapy.

Fibroadenomas are the most common benign breast tumors in women, with a peak incidence in the second and third decades of life. They are less common in postmenopausal women. The prevalence of fibroadenoma varies by population, but it is estimated that about 10% of women will develop a fibroadenoma at some point in their lives.

Fibroadenomas are composed of both stromal (connective tissue) and epithelial (glandular tissue) components. They arise from the lobular units of the breast, where the glandular tissue is located. The growth of fibroadenomas is thought to be influenced by hormonal factors, particularly estrogen, which stimulates the proliferation of both stromal and epithelial cells.

There are no specific measures to prevent fibroadenomas, as their exact cause is not fully understood. However, maintaining a healthy lifestyle, including a balanced diet and regular exercise, may help regulate hormonal levels and potentially reduce the risk of developing fibroadenomas.

Fibroadenoma is a common benign breast tumor that typically affects young women. It presents as a painless, mobile lump in the breast and is diagnosed through clinical examination and imaging. Treatment is often not necessary, but surgical removal or minimally invasive procedures can be considered if the tumor is large or symptomatic. The prognosis is excellent, with no increased risk of breast cancer.

If you have been diagnosed with a fibroadenoma, it is important to understand that this is a benign condition and not cancer. Regular monitoring with your healthcare provider is usually sufficient to ensure that the fibroadenoma does not change over time. If you experience any new symptoms or changes in the lump, contact your doctor for further evaluation.

1. Dupont WD, Page DL, Parl FF, et al. Long-term risk of breast cancer in women with fibroadenoma. N Engl J Med. 1994;331(1):10–15.
2. Wu YT, Chen ST, Chen CJ, et al. Breast cancer arising within fibroadenoma: collective analysis of case reports in the literature and hints on treatment policy. World J Surg Oncol. 2014;12(1):335.
3. Williamson ME, Lyons K, Hughes LE. Multiple fibroadenomas of the breast: a problem of uncertain incidence and management. Ann R Coll Surg Engl. 1993;75(3):161–163.
4. Song BS, Kim EK, Seol H, et al. Giant juvenile fibroadenoma of the breast: a case report and brief literature review. Ann Pediatr Endocrinol Metab. 2014;19(1):45–48.
5. Chung EM, Cube R, Hall GJ, González C, Stocker JT, Glassman LM. From the archives of the AFIP: breast masses in children and adolescents: radiologic-pathologic correlation. Radiographics. 2009;29(3):907–931.
6. Greenberg R, Skornick Y, Kaplan O. Management of breast fibroadenomas. J Gen Intern Med. 1998;13(9):640–645.
7. Garcia CJ, Espinoza A, Dinamarca V, et al. Breast US in children and adolescents. Radiographics. 2000;20(6):1605–1612.
8. Smith RA. The evolving role of MRI in the detection and evaluation of breast cancer. N Engl J Med. 2007;356(13):1362-1364.
9. Harvey JA, Nicholson BT, Lorusso AP, Cohen MA, Bovbjerg VE. Short-term follow-up of palpable breast lesions with benign imaging features: evaluation of 375 lesions in 320 women. AJR Am J Roentgenol. 2009;193(6):1723–1730.